Loading
Obesity · Journal article
Journal of the International Society of Sports Nutrition · September 1, 2026
Encouraging direction, but not yet definitive.
This is a single-centre, quasi-randomized 12-week trial in 60 overweight adults showing statistically significant reductions in body weight (−1.93 kg), waist circumference (−1.83 cm), and triglycerides, alongside improved HDL cholesterol and no reported safety signals. The evidence is encouraging but limited by modest sample size, quasi-randomization, lack of long-term follow-up, and reliance on surrogate endpoints; confirmation in a larger, fully randomized trial is needed before drawing conclusions about clinical utility.
Double-blind, quasi-randomized, placebo-controlled clinical trial. Overweight subjects aged 20–70 years. Intervention: Coleus forskohlii extract (Forcslim). Compared with: Placebo. n = 60.
Body weight reduction in Forcslim group: −1.93 kg compared to placebo (p < 0.001) Waist circumference reduction in Forcslim group: −1.83 cm compared to placebo (p < 0.01) Triglyceride levels significantly reduced in Forcslim group (p < 0.01)
Study duration is 12 weeks; long-term efficacy and safety are unknown No clinically significant adverse effects or changes in metabolic, hepatic, or cardiovascular safety markers
Clinicians should interpret these findings as preliminary evidence that Coleus forskohlii supplementation may support modest weight loss and favourable lipid changes in overweight adults, but the small sample size, quasi-randomization, and lack of long-term safety and efficacy data preclude strong recommendations. Confirmation in a larger, fully randomized trial is essential before incorporation into clinical practice.
A small, adequately controlled 12-week RCT of a botanical supplement showing statistically significant reductions in body weight, waist circumference, and triglycerides with a favourable safety profile, but limited by modest sample size, quasi-randomization, and surrogate endpoints rather than hard clinical outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should interpret these findings as preliminary evidence that Coleus forskohlii supplementation may support modest weight loss and favourable lipid changes in overweight adults, but the small sample size, quasi-randomization, and lack of long-term safety and efficacy data preclude strong recommendations. Confirmation in a larger, fully randomized trial is essential before incorporation into clinical practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Overweight and obesity have emerged as a global epidemic, significantly impacting human health. Traditional usage and growing scientific evidence suggest that Coleus forskohlii extract (Forcslim) may aid in reducing excess body weight and fat. This study aimed to evaluate the efficacy and safety of Forcslim supplementation in overweight individuals.Methods. A quasi-randomized, double-blind, placebo-controlled clinical trial was conducted in 60 overweight subjects aged 20-70 years over a period of 12 weeks. The participants were assigned to receive either Forcslim or placebo. The key outcome measures included body weight, body mass index (BMI), body composition, and anthropometric parameters. Additionally, lipid profile parameters and safety markers (including metabolic, hepatic, and cardiovascular indicators) were assessed throughout the study duration.Results. Compared to the placebo group, the Forcslim group showed significant reductions in waist circumference (-1.83 cm; p < 0.01) and body weight (-1.93 kg; p < 0.001). Significant improvements in anthropometric parameters were observed exclusively in the Forcslim group. Furthermore, triglyceride (TG) levels were significantly reduced (p < 0.01), while high-density lipoprotein (HDL) levels showed a significant increase (p = 0.001). No clinically significant changes were observed in metabolic markers, liver and muscle enzyme levels, heart rate, blood pressure, or reported adverse effects, indicating a favorable safety profile.Conclusions. Forcslim demonstrated significant anti-obesity effects, including reductions in body weight, waist circumference, and improvements in the lipid profile. These findings suggest that C. forskohlii extract supplementation may serve as a safe and effective alternative to synthetic anti-obesity drugs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.